Wave Life Sciences Ltd

For the period ended Dec 31, 2023. Filed Mar 6, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 6, 2024

WVE$3.48+3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share amounts)

	December 31, 2023	December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$200,351	$88,497
Accounts receivable	21,086	—
Prepaid expenses	9,912	7,932
Other current assets	4,024	2,108
Total current assets	235,373	98,537
Long-term assets:
Property and equipment, net of accumulated depreciation of $42,709 and $37,846 as of December 31, 2023 and 2022, respectively	13,084	17,284
Operating lease right-of-use assets	22,637	26,843
Restricted cash	3,699	3,660
Other assets	156	62
Total long-term assets	39,576	47,849
Total assets	$274,949	$146,386
Liabilities, Series A preferred shares and shareholders’ equity (deficit)
Current liabilities:
Accounts payable	$12,839	$16,915
Accrued expenses and other current liabilities	16,828	17,552
Current portion of deferred revenue	150,059	31,558
Current portion of operating lease liability	6,714	5,496
Total current liabilities	186,440	71,521
Long-term liabilities:
Deferred revenue, net of current portion	15,601	79,774
Operating lease liability, net of current portion	25,404	32,118
Other liabilities	—	190
Total long-term liabilities	41,005	112,082
Total liabilities	$227,445	$183,603
Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at December 31, 2023 and 2022	$7,874	$7,874
Shareholders’ equity (deficit):
Ordinary shares, no par value; 119,162,234 and 86,924,643 shares issued and outstanding at December 31, 2023 and 2022, respectively	$935,367	$802,833
Additional paid-in capital	129,237	119,442
Accumulated other comprehensive loss	(124)	(29)
Accumulated deficit	(1,024,850)	(967,337)
Total shareholders’ equity (deficit)	39,630	(45,091)
Total liabilities, Series A preferred shares and shareholders’ equity (deficit)	$274,949	$146,386

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.